Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axovant Sciences (NYSE: AXON), Savara Inc (NASDAQ: SVRA) and Pacira Pharmaceuticals (NASDAQ: PCRX)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axovant Sciences (NYSE: AXON), Savara Inc (NASDAQ: SVRA) and Pacira Pharmaceuticals (NASDAQ: PCRX).

Axovant Sciences (NYSE: AXON)

Cowen & Co. analyst Ritu Baral assigned a Hold rating to Axovant Sciences (NYSE: AXON) yesterday. The company’s shares opened today at $1.81, close to its 52-week low of $1.47.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 30.5% and a 53.7% success rate. Baral covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Axovant Sciences is Moderate Buy and the average price target is $5.90, representing a 226.0% upside.

In a report released yesterday, Jefferies also reiterated a Hold rating on the stock with a $3 price target.
Savara Inc (NASDAQ: SVRA)

In a report released yesterday, Dewey Steadman from Canaccord Genuity maintained a Buy rating on Savara Inc (NASDAQ: SVRA), with a price target of $25. The company’s shares opened today at $12.50.

Steadman commented:

“We maintain our BUY rating and $25 PT for SVRA shares.”

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -8.3% and a 30.6% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, ANI Pharmaceuticals Inc, and Pacira Pharmaceuticals.

Savara Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.

Pacira Pharmaceuticals (NASDAQ: PCRX)

Cowen & Co. analyst Boris Peaker assigned a Hold rating to Pacira Pharmaceuticals (NASDAQ: PCRX) yesterday. The company’s shares opened today at $35.90.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.9% and a 45.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Madrigal Pharmaceuticals Inc, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is Moderate Buy and the average price target is $49.63, representing a 38.2% upside.

In a report issued on January 29, Canaccord Genuity also maintained a Hold rating on the stock with a $42 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.